DOCSLIB.ORG

Discovery and Reconstitution of the Cycloclavine Biosynthetic Pathway - Enzymatic Formation of a Cyclopropyl Group

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Discovery and Reconstitution of the Cycloclavine Biosynthetic Pathway - Enzymatic Formation of a Cyclopropyl Group Discovery and Reconstitution of the Cycloclavine Biosynthetic Pathway - Enzymatic Formation of a Cyclopropyl Group Dorota Jakubczyk, Lorenzo Caputi, Anaëlle Hatsch, Curt A. F. Nielsen, Melanie Diefenbacher, Jens Klein, Andrea Molt, Hartwig Schröder, Johnathan Z. Cheng, Michael Naesby, and Sarah E. O’Connor ACIE, 2015, 54, 5117-5121 CO2H N NH2 H O O 8 enzymes + P P N O O O H O O L-tryptophan DMAPP NH cycloclavine Steph McCabe Wipf Group- Current Literature 27th June 2015 Steph McCabe@ Wipf Group Slide 1 of 12 6/27/15 N H Ergot Alkaloids NH • Ergot alkaloids are produced by fungi of the Clavicipitaceae and Trichocomaceae families, which infect the seeds of grass or grains • Consumption of ergot contaminated grains leads to ergotism (St. Anthony’s fire); § ergotismus convulsivus characterized by hallucinations and paranoia § ergotismus gangrenous characterized by gangrene of the feet, legs, hands and arms • Ergot alkaloids are characterized by the presence of a tetracyclic Ergoline core and can be further classified into Lysergic acid or Clavine subclasses based on the oxidation state of the substituent at C8 8 NH D H HO2C 8 Me 8 NH C NH D H D H A B 2 C C N H 1 Ergot on wheat stalks A B 2 Ergoline Core A B 2 N N H 1 H 1 Lysergic acid subclass Clavine subclass O O N N NH O Et2N OH H O N O NH N N H H H H H NH NH NH NH ergotamine Lysergic acid diethylamide (LSD) festuclavine cycloclavine Wallwey, C. and Li, S.,Nat. Prod. Rep., 2011, 28, 496 Jakubczyk, D., Cheng, J. Z. and O’Connor, S., Nat. Prod. Rep., 2014, 31, 1328 Steph McCabe@ Wipf Group Slide 2 of 12 6/27/15 N H Biological Activity NH • The broad spectrum of bioactivity exhibited by ergot alkaloids is related to their ability to act as an agonist or antagonist toward neuroreceptors for dopamine, serotonin and adrenaline. 7 8 6 NH H 9 10 5 4 H11 16 3 12 2 13 1 15 NH 14 Ergoline 6 6 NH2 NHMe 6 NH2 5 HO 5 5 10 10 4 11 11 11 HO 16 3 12 16 12 16 12 2 13 13 13 1 15 15 15 N HO 14 HO 14 14 H OH OH serotonin (5-HT) dopamine (DA) epinephrine (adrenalin) Jakubczyk, D., Cheng, J. Z. and O’Connor, S., Nat. Prod. Rep., 2014, 31, 1328 Steph McCabe@ Wipf Group Slide 3 of 12 6/27/15 N H Examples of FDA Approved Drugs with an Ergoline Core NH Br OH N OH NH NH O O O N H O N N H H O N NH R N Ergometrine R = Me R = H Me Nicergoline Use: induces contractions, Methysergide Methylergometrine Use: treatment of senile prevents post partum Use migraine treatment Use: prevents post partum dementia haemorrhage MOA: antagonist of haemorrhage, migraine treatment MOA: partial agonist/antagonist of MOA: alpha-1A adrenergic Mechanism of Action (MOA): serotonin 5-HT2B receptors receptor antagonist acts on alpha-adrenergic serotonergic, dopaminergic and serotonergic receptors and alpha adrenergic receptors N O NH O N N NH O N O S N H OH O N H O N H H H H Br NH NH NH Pergolide Cabergoline Bromocriptine Use: treatment of Parkinson’s Disease Use: treatment of Use: treatment of pituitary tumors, MOA: agonist of dopaminergic receptors hyperprolactinaemia Parkinson's disease, (*withdrawn from the US market in 2007 and Parkinson's disease hyperprolactinaemia, due to increased risk of cardiac MOA: agonist of MOA: agonist valvulopathy) dopamine D2 receptors. of dopamine D2 receptors DrugBank 4.0: Nucleic Acids Res., 2014, 42(1),1091-7. Steph McCabe@ Wipf Group Slide 4 of 12 6/27/15 N H Cycloclavine NH N H NH Cycloclavine • First isolated in 1969 from the seeds of the African morning glory (Ipomea hildebrandtii) by Hoffman and co-workers • Subsequently isolated Aspergillus japonicus, a species of in filamentous fungus • Absolute configuration assigned from X-ray crystallographic analysis of the methobromide salt • No significant biological activities reported thus far Ipomea hildebrandtii • 3 total syntheses, including an earlier synthesis from our group in 14 linear steps and 1.2% overall yield steps Boc O N 1. IMDAF OH HN 2. LAH N N HO H H CO2Me (±)-cycloclavine Hofmann et. al.,Tetrahedron, 1969, 25, 5879 Furuta, T., et al., Agric. Biol. Chem., 1982, 46, 1921 Incze, M., et al., Tetrahedron, 2008, 64, 2924 Petronijevic, F. R. and P. Wipf JACS, 2011, 133, 7704 Jabre, N. D., et al. ,Tetradhedron Lett,, 2014, 56, 197 Steph McCabe@ Wipf Group Slide 5 of 12 6/27/15 N Biosynthetic Pathway Elucidation: H Reconstitution of the Ergot Alkaloid Synthesis (EAS) Genes NH • All ergot alkaloids are derived from common a biosynthetic intermediate - chanoclavine-I. The mechanisms of most downstream biosynthetic transformations are unknown • Recently a 16.8 kbp biosynthetic cluster, containing 8 genes in the genome of cycloclavine producer Aspergillus japonicus was identified (O'Connor et al) • 7 genes are homologous to genes previously implicated in the biosynthesis of festuclavine or agroclavine. • Role of easH unknown equipped with a 1.7mm cryogenic TCI probe. The structure of cycloclavine 6 was solved by H 1 13 1 1 1 13 lysergic acid N means H-NMR, C-NMR, H, H-ROESY, and H, C-HMBC.subclass H OH O HN SI-2 Supporting Figures agroclavine H H EasD/ FgaDH H H N N H Figure S1 Organization of the AspergillusH japonicus cycloclavine 6 gene cluster NAD NADH HN HN H N ?? N chanoclavine-I chanoclavine-I aldehyde clavine subclass H H NAD NADH HN HN festuclavine cycloclavine Steph McCabe@ Wipf Group Slide 6 of 12 6/27/15 13 N Biosynthetic Pathway Elucidation: H Reconstitution of the Ergot Alkaloid Synthesis (EAS) Genes NH • This paper aimed to validate whether this cluster was responsible for cycloclavine biosynthesis by reconstitution of the eight genes in S. cerevisiae • Chanoclavine-I was synthesized by heterologous expression of dmaW, easF, easE and easC in a S. cerevisiae strain CO2H CO2H DmaW/ EasF/ NH2 prenyl transferase NH2 methyl transferase N DMAPP PPi N SAM S-homo H H cysteine L-tryptophan DMAT OH HN H H EasE/ oxidase N EasC/ catalase H CO2H N HN H Chanoclavine-I N-Me-DMAT Microbial Cell Factories, 2014, 13, 95 Nat. Prod. Rep., 2011, 28, 496 Steph McCabe@ Wipf Group Slide 7 of 12 6/27/15 Angewandte. Communications N Biosynthetic Pathway Elucidation: H Reconstitution of the Ergot Alkaloid Synthesis (EAS) Genes NH • In Vivo transformation of the chanoclavine-I producing strain with easD, easA, and easG produced festuclavine • Addition of easH produced cycloclavine as the major product along with festuclavine • In vitro incubation of chanoclavine-I aldehyde with easA, eas G easH produced cycloclavine • Cycloclavine was reconstituted in S. cerevisiae with a final concentration of 529 mg. L-1 OH O easD/ eas A/ H H H H Reductase N oxidase N H H NAD NADH NADH NAD HN HN chanoclavine-I chanoclavine-I aldehyde H eas G/ N Reductase H O NADH NAD HN festuclavine H H N H N H N H HN H easH/ eas G/ incubation of chanoclavine-I aldehyde dioxygenase Reductase with easA, eas G and easH HN HN cycloclavine festuclavineFigure 1. Ergot-alkaloid biosynthetic pathway. a) Biosynthesis of festuclavine (4), agroclavine (5), and cycloclavine (6) from l-tryptophan and NADH NAD optimised ratio > 7:1 dimethylallyl pyrophosphate (DMAPP). b) LC–MS chromatograms showing that EasA, EasG, and EasH are required to generate cycloclavine (6) from chanoclavine-I aldehyde (3). i–iv) Authentic standards of chanoclavine-I aldehyde (3; i), agroclavine (5; ii), festuclavine (4; iii), and cycloclavine (6, iv). v,vi) Reaction products from the incubation of Aj_EasA, Aj_EasG, and Aj_EasH with chanoclavine-I aldehyde (3) and cofactors: Steph McCabe@ Wipf Group Slide 8 of 12 v) by-product, festuclavine (4); vi) predominant enzymatic6/27/15 product, cycloclavine (6). both cycloclavine (6) and festuclavine (4) have been isolated derivatized ergot alkaloids have not been subject to such from A. japonicus,[3a] we hypothesize that this gene cluster efforts. To examine whether we could produce the complex produces a mixture of these two compounds in the native ergot alkaloid cycloclavine (6) in high yields in S. cerevisiae, host, though how this ratio is impacted by environmental we integrated multiple copies of cycloclavine-pathway genes conditions is unknown. To assess whether increased amounts into the genome of the commonly used yeast strain S288C. of EasH would impact the festuclavine/cycloclavine ratio, we The best strain had an additional copy of easG, two additional constructed a strain carrying the entire eight-gene cluster copies of dmaW and easD, and three additional copies of easC supplemented with additional copies of easH from plasmid and easH. Moreover, additional copies of the host genes pdi1 vectors. We observed a clear gene-dose-dependent increase in (protein disulfide isomerase) and fad1 (FAD synthetase) the ratio of cycloclavine (6) to festuclavine (4) as the copy were also included to assist in the production of the disulfide- number of easH increased (see Figure S4). and flavin-containing enzyme EasE (see Table S1 in the Complex ergot alkaloids constitute a rich source of Supporting Information). This strain resulted in the produc- biologically active compounds, and a robust production tion of cycloclavine (6) with a final concentration of 1 platform for these molecules will improve accessibility and 529 mgLÀ in the growth medium when fermentation was prospects for commercial application. Whereas chanoclavine- carried out for 160 h in a 1 L fermenter and a fed-batch I(2) has been successfully reconstituted in S.
Load more

Recommended publications
  • 4/23/2015 1 •Psychedelics Or Hallucinogens
    4/23/2015 Hallucinogens •Psychedelics or This “classic” hallucinogen column The 2 groups below are quite different produce similar effects From the classic hallucinogens Hallucinogens Drugs Stimulating 5HT Receptors Drugs BLOCKING ACH Receptors • aka “psychotomimetics” LSD Nightshade(Datura) Psilocybin Mushrooms Jimsonweed Morning Glory Seeds Atropine Dimethyltryptamine Scopolamine What do the very mixed group of hallucinogens found around the world share in common? •Drugs Resembling NE Drugs BLOCKING Glutamate Receptors •Peyote cactus Phencyclidine (PCP) •Mescaline Ketamine All contain something that resembles a •Methylated amphetamines like MDMA High dose dextromethorphan •Nutmeg neurotransmitter •New synthetic variations (“bath salts”) •5HT-Like Hallucinogens •LSD History • Serotonin • created by Albert Hofmann for Sandoz Pharmaceuticals LSD • was studying vasoconstriction produced by ergot alkaloids LSD • initial exposure was accidental absorption thru skin • so potent ED is in millionths of a gram (25-250 micrograms) & must be delivered on something else (sugar cube, gelatin square, paper) Psilocybin Activate 5HT2 receptors , especially in prefrontal cortex and limbic areas, but is not readily metabolized •Characteristics of LSD & Other “Typical” •Common Effects Hallucinogens • Sensory distortions (color, size, shape, movement), • Autonomic (mostly sympathetic) changes occur first constantly changing (relatively mild) • Vivid closed eye imagery • Sensory/perceptual changes follow • Synesthesia (crossing of senses – e.g. hearing music
    [Show full text]
  • Inline-Supplementary-Material-1.Pdf
    Appendix 1: STOPP/START criteria version 2 applied to the TRUST dataset Physiological system Criteria Criteria included Number (%) (The relevant () criteria for each participant were applied to the dataset and recorded in of Microsoft Office Excel ® (2013)) criteria included out of total criteria STOPP criteria Indication of medication A1. Any drug prescribed without an evidence-based clinical indication. X 1/3 (33.3) A2. Any drug prescribed beyond the recommended duration, where treatment duration is X well defined. A3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent). Cardiovascular system B1. Digoxin for heart failure with preserved systolic ventricular function (no clear evidence X 7/13 (53.8) of benefit). B2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). B3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). B4. Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or complete heart block (risk of profound hypotension, asystole). B5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias X (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem). B6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). B7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually more appropriate). B8. Thiazide diuretic with current significant hypokalaemia (i.e.
    [Show full text]
  • Pericardial, Retroperitoneal, and Pleural Fibrosis Induced by Pergolide
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.66.1.79 on 1 January 1999. Downloaded from J Neurol Neurosurg Psychiatry 1999;66:79–81 79 SHORT REPORT Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide S Shaunak, A Wilkins, J B Pilling, D J Dick Abstract 1992, the emergence of motor fluctuations led Three patients with Parkinson’s disease to the introduction of pergolide, and the dose are described who developed pericardial, of this was gradually increased to a maximum retroperitoneal, and pleural fibrosis asso- of 1mg/day. 1n 1994, 2 years after the ciated with pergolide treatment. Surgical introduction of pergolide, the patient devel- intervention was required in all three oped left flank pain with weight loss, and was cases, either to reach a tissue diagnosis or found to have a mild anaemia (haemoglobin for potentially life threatening complica- 10.4 g/dl), with indices suggesting iron defi- tions. Symptoms emerged on average 2 ciency, and an ESR of 40 mm/h. Upper gastro- years after the institution of treatment, intestinal endoscopy and barium enema gave and were suYciently non-specific to cause negative results. Seven months later right sided significant delays in diagnosis in all cases. chest pain and a non-productive cough devel- The erythrocyte sedimentation rate (ESR) oped; investigations confirmed persistent anae- was raised in the two patients in whom it mia, an ESR of 55 mm/h, and bilateral pleural was measured. Serosal fibrosis is a rarely thickening on chest radiography and CT. Lung reported adverse eVect of pergolide treat- function tests showed a reduction in total lung ment, although it is well described with capacity of 36% with no fall in transfer factor, other dopamine agonists.
    [Show full text]
  • PDF Download
    CURRENT THERAPEUTIC RESEARCH VOL. 56, NO. 5, MAY 1995 EFFECTS OF CEREBRAL METABOLIC ENHANCERS ON BRAIN FUNCTION IN RODENTS KOICHIRO TAKAHASHI,l MINORU YAMAMOTO,’ MASANORI SUZUKI,’ YUKIKO OZAWA,’ TAKASHI YAMAGUCHI,l HIROFUMI ANDOH, AND KOUICHI ISHIKAWA2 ‘Department of Pharmacology, Clinical Pharmacology Research Laboratory, Yamunouchi Pharmaceutical Co. Ltd., and ‘Department of Pharmacology, School of Medicine, Nihon University, Tokyo, Japan AFWI’RACT The effects of cerebral metabolic enhancers (indeloxazine, bi- femelane, idebenone, and nicergoline) on reserpine-induced hypother- mia, the immobility period in forced swimming tests, and passive avoidance learning behavior were compared with the effects of ami- triptyline in rodents. Indeloxazine, bifemelane, and amitriptyline antagonized hypothermia in mice given reserpine. Indeloxaxine and amitriptyline decreased the immobility period in mice in the forced swimming test in a dose-dependent manner. The latency of step- through in the passive avoidance test in rats was prolonged by ad- ministration of indeloxazine but shortened by administration of amitriptyline. Neither idebenone nor nicergoline displayed any phar- macologic action in these tests. The results suggest that indeloxaxine possesses an antidepressant activity similar to that of amitriptyline but differs from amitriptyline in its anticholinergic properties and its ability to ameliorate impaired brain function such as that of learning behavior. In addition, indeloxazine exhibited broader effects on brain functions than either bifemelane, idebenone, or nicergoline. INTRODUCTION Cerebral metabolic enhancers (drugs that enhance energy metabolism) including brain glucose and ATP levels such as indeloxazine,1*2 bi- femelane, 3*4idebenone?6 and nicergoline,7>8 are currently used for the treatment of patients with various psychiatric symptoms. These symptoms include reduced spontaneity and emotional disturbance in patients with cerebral vascular disease.
    [Show full text]
  • Evidence from Horses with Pituitary Pars Intermedia Dysfunction Jessica S
    Fortin et al. BMC Veterinary Research (2020) 16:356 https://doi.org/10.1186/s12917-020-02565-3 RESEARCH ARTICLE Open Access Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction Jessica S. Fortin1*, Matthew J. Benskey2, Keith J. Lookingland2, Jon S. Patterson1, Erin B. Howey1, John L. Goudreau2,3 and Harold C. Schott II4* Abstract Background: Pituitary pars intermedia dysfunction (PPID) develops slowly in aged horses as degeneration of hypothalamic dopaminergic neurons leads to proliferation of pars intermedia (PI) melanotropes through hyperplasia and adenoma formation. Dopamine (DA) concentrations and tyrosine hydroxylase (TH) immunoreactivity are markedly reduced in PI tissue of PPID-affected equids and treatment with the DA receptor agonist pergolide results in notable clinical improvement. Thus, we hypothesized that pergolide treatment of PPID-affected horses would result in greater DA and TH levels in PI tissue collected from PPID-affected horses versus untreated PPID-affected horses. To test this hypothesis, pituitary glands were removed from 18 horses: four untreated PPID-affected horses, four aged and four young horses without signs of PPID, and six PPID-affected horses that had been treated with pergolide at 2 µg/kg orally once daily for 6 months. DA concentrations and TH expression levels in PI tissues were determined by high performance liquid chromatography with electrochemical detection and Western blot analyses, respectively. Results: DA and TH levels were lowest in PI collected from untreated PPID-affected horses while levels in the pergolide treated horses were similar to those of aged horses without signs of PPID.
    [Show full text]
  • Cabergoline Patient Handout
    Cabergoline For the Patient: Cabergoline Other names: DOSTINEX® • Cabergoline (ca-BERG-go-leen) is used to treat cancers that cause the body to produce too much of a hormone called prolactin. Cabergoline helps decrease the size of the cancer and the production of prolactin. It is a tablet that you take by mouth. • Tell your doctor if you have ever had an unusual or allergic reaction to bromocriptine or other ergot derivatives, such as pergoline (PERMAX®) and methysergide (SANSERT®), before taking cabergoline. • Blood tests and blood pressure measurement may be taken while you are taking cabergoline. The dose of cabergoline may be changed based on the test results and/or other side effects. • It is important to take cabergoline exactly as directed by your doctor. Make sure you understand the directions. Take cabergoline with food. • If you miss a dose of cabergoline, take it as soon as you can if it is within 2 days of the missed dose. If it is over 2 days since your missed dose, skip the missed dose and go back to your usual dosing times. • Other drugs such as azithromycin (ZITHROMAX®), clarithromycin (BIAXIN®), erythromycin, domperidone, metoclopramide, and some drugs used to treat mental or mood problems may interact with cabergoline. Tell your doctor if you are taking these or any other drugs as you may need extra blood tests or your dose may need to be changed. Check with your doctor or pharmacist before you start or stop taking any other drugs. • The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of cabergoline.
    [Show full text]
  • Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters
    Year of edition: 2018 Authors of the text: Marc Aixalà & José Carlos Bouso Edition: Alex Verdaguer | Genís Oña | Kiko Castellanos Illustrations: Alba Teixidor EU Project: New Approaches in Harm Reduction Policies and Practices (NAHRPP) Special thanks to collaborators Alejandro Ponce (in Peyote report) and Eduardo Carchedi (in Kambó report). TECHNICAL REPORT ON PSYCHOACTIVE ETHNOBOTANICALS Volumes I - II - III ICEERS International Center for Ethnobotanical Education Research and Service INDEX SALVIA DIVINORUM 7 AMANITA MUSCARIA 13 DATURA STRAMONIUM 19 KRATOM 23 PEYOTE 29 BUFO ALVARIUS 37 PSILOCYBIN MUSHROOMS 43 IPOMOEA VIOLACEA 51 AYAHUASCA 57 IBOGA 67 KAMBÓ 73 SAN PEDRO 79 6 SALVIA DIVINORUM SALVIA DIVINORUM The effects of the Hierba Pastora have been used by Mazatec Indians since ancient times to treat diseases and for divinatory purposes. The psychoactive compound Salvia divinorum contains, Salvinorin A, is the most potent naturally occurring psychoactive substance known. BASIC INFO Ska Pastora has been used in divination and healing Salvia divinorum is a perennial plant native to the Maza- rituals, similar to psilocybin mushrooms. Maria Sabina tec areas of the Sierra Madre Oriental Mountains of Mexi- told Wasson and Hofmann (the discoverers of its Mazatec co. Its habitat is tropical forests, where it grows between usage) that Salvia divinorum was used in times when the- 300 and 800 meters above sea level. It belongs to the re was a shortage of mushrooms. Some sources that have Lamiaceae family, and is mainly reproduced by cuttings done later feldwork point out that the use of S. divinorum since it rarely produces seeds. may be more widespread than originally believed, even in times when mushrooms were abundant.
    [Show full text]
  • Biased Ligands Differentially Shape the Conformation of The
    International Journal of Molecular Sciences Article Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors Katrin Denzinger, Trung Ngoc Nguyen, Theresa Noonan, Gerhard Wolber and Marcel Bermudez * Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Strasse 2-4, 14195 Berlin, Germany; [email protected] (K.D.); [email protected] (T.N.N.); [email protected] (T.N.); [email protected] (G.W.) * Correspondence: [email protected] Received: 22 November 2020; Accepted: 18 December 2020; Published: 20 December 2020 Abstract: G protein-coupled receptors are linked to various intracellular transducers, each pathway associated with different physiological effects. Biased ligands, capable of activating one pathway over another, are gaining attention for their therapeutic potential, as they could selectively activate beneficial pathways whilst avoiding those responsible for adverse effects. We performed molecular dynamics simulations with known β-arrestin-biased ligands like lysergic acid diethylamide and ergotamine in complex with the 5-HT2B receptor and discovered that the extent of ligand bias is directly connected with the degree of closure of the extracellular loop region. Given a loose allosteric coupling of extracellular and intracellular receptor regions, we delineate a concept for biased signaling at serotonin receptors, by which conformational interference with binding pocket closure restricts the signaling repertoire of the receptor. Molecular docking studies of biased ligands gathered from the BiasDB demonstrate that larger ligands only show plausible docking poses in the ergotamine-bound structure, highlighting the conformational constraints associated with bias. This emphasizes the importance of selecting the appropriate receptor conformation on which to base virtual screening workflows in structure-based drug design of biased ligands.
    [Show full text]
  • Ergot Alkaloids As Dopamine Agonists: Comparison in Two Rodent Models
    European Journal of Pharmacology, 37 (1976) 295-302 295 © North-Holland Publishing Company, Amsterdam - Printed in The Netherlands ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS GILL ANLEZARK, CHRIS PYCOCK and BRIAN MELDRUM Department of Neurology, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, U.K. Received 18 December 1975, revised MS received 20 February 1976, accepted 26 February 1976 G. ANLEZARK, C. PYCOCK and B. MELDRUM, Ergot alkaloids as dopamine agonists: comparison in two rodent models, European J. Pharmacol. 37 (1976) 295-302. A series of ergot alkaloids, together with the DA agonists apomorphine and piribedil, were tested for protec- tive effects against audiogenic seizures in an inbred strain of mice (DBA/2) and for induction of circling behaviour in mice with unilateral destruction of one nigrostriatal DA pathway. The order of potency against audiogenic sei- zures was apomorphine> ergocornine> bromocryptine > ergometrine> LSD> methysergide > piribedil while that observed in the rotating mouse model was apomorphine> ergometrine> ergocornine> brornocryptine > piribedil. LSD caused only weak circling behaviour even when administered in high doses (> 1 mg/kg). Methyser- gide was ineffective. Prior administration of the neuroleptic agent haloperidol blocked the effect of DA agonists and of ergot alkaloids in both animal models. The possible action of ergot alkaloids as DA agonists is discussed. Ergot alkaloids Audiogenic seizures Dopamine agonists Circling behaviour 1. Introduction gic synapses, in two rodent pharmacological models. The first model studied is 'audiogen- The pharmacology of the ergot alkaloids is ic' seizures in genetically susceptible mice. complex and not well understood. Peripheral- The severity of the seizure responses to audi- ly, they act on smooth muscle as 5-hydroxy- tory stimulation can be modified by a variety tryptamine (5-HT) antagonists (Goodman and of drugs believed to act on monoaminergic Gilman, 1971) and as a-adrenergic blockers transmission in the brain (Lehmann, 1970).
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • Ergot Alkaloid Biosynthesis in Aspergillus Fumigatus : Association with Sporulation and Clustered Genes Common Among Ergot Fungi
    Graduate Theses, Dissertations, and Problem Reports 2009 Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Coyle, Christine M., "Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi" (2009). Graduate Theses, Dissertations, and Problem Reports. 4453. https://researchrepository.wvu.edu/etd/4453 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Ergot alkaloid biosynthesis in Aspergillus fumigatus: Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle Dissertation submitted to the Davis College of Agriculture, Forestry, and Consumer Sciences at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Genetics and Developmental Biology Daniel G. Panaccione, Ph.D., Chair Kenneth P. Blemings, Ph.D. Joseph B.
    [Show full text]
  • Risk Assessment of Argyreia Nervosa
    Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos RIVM letter report 2019-0210 Colophon © RIVM 2020 Parts of this publication may be reproduced, provided acknowledgement is given to the: National Institute for Public Health and the Environment, and the title and year of publication are cited. DOI 10.21945/RIVM-2019-0210 W. Chen (author), RIVM L. de Wit-Bos (author), RIVM Contact: Lianne de Wit Department of Food Safety (VVH) [email protected] This investigation was performed by order of NVWA, within the framework of 9.4.46 Published by: National Institute for Public Health and the Environment, RIVM P.O. Box1 | 3720 BA Bilthoven The Netherlands www.rivm.nl/en Page 2 of 42 RIVM letter report 2019-0210 Synopsis Risk assessment of Argyreia nervosa In the Netherlands, seeds from the plant Hawaiian Baby Woodrose (Argyreia nervosa) are being sold as a so-called ‘legal high’ in smart shops and by internet retailers. The use of these seeds is unsafe. They can cause hallucinogenic effects, nausea, vomiting, elevated heart rate, elevated blood pressure, (severe) fatigue and lethargy. These health effects can occur even when the seeds are consumed at the recommended dose. This is the conclusion of a risk assessment performed by RIVM. Hawaiian Baby Woodrose seeds are sold as raw seeds or in capsules. The raw seeds can be eaten as such, or after being crushed and dissolved in liquid (generally hot water).
    [Show full text]